z-logo
Premium
Cardiac PPARα expression in patients with dilated cardiomyopathy
Author(s) -
Schupp Michael,
Kintscher Ulrich,
Fielitz Jens,
Thomas Jennifer,
Pregla Reinhard,
Hetzer Roland,
Unger Thomas,
RegitzZagrosek Vera
Publication year - 2006
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2005.09.003
Subject(s) - medicine , dilated cardiomyopathy , carnitine , endocrinology , heart failure , peroxisome proliferator activated receptor , cardiomyopathy , beta oxidation , peroxisome , diabetic cardiomyopathy , gene expression , cardiology , receptor , metabolism , biology , gene , biochemistry
Background: The peroxisome proliferator‐activated receptor alpha (PPARα) is a central regulator of myocardial fatty acid (FA) metabolism implicated in the pathogenesis of heart failure. Aims: To characterize PPARα regulation in human dilated cardiomyopathy (DCM), we studied the expression of cardiac PPARα, cardiac carnitine palmitoyl‐transferase I (CPT‐1), a major PPARα target gene, and of the cardiac glucose transporter GLUT‐4 in patients with DCM. Methods: Left ventricular biopsies were taken from patients with DCM ( n =16) and control subjects ( n =15), and mRNA expression was quantitated using real‐time PCR (SYBR ® Green) and protein expression was measured by Western immunoblotting. Results: Left ventricular PPARα mRNA levels were significantly increased in the DCM group compared to the control group (136±25.4% vs. control, p <0.01). Consistently, DCM patients had a significantly higher cardiac CPT‐1 mRNA expression (147±51% vs. control, p <0.05) compared to the control group. Cardiac GLUT‐4 expression was similar in both groups. Conclusion: Elevated cardiac PPARα levels followed by an induction of cardiac CPT‐1 expression may result in increased fatty acid metabolism for cardiac energy production in DCM, suggesting a specific cardiac metabolic program in human DCM compared to other types of cardiomyopathy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here